Production of tumor-specific suppressor T cell hybridomasBEAR, H. D.The Journal of surgical research. 1987, Vol 42, Num 4, pp 369-376, issn 0022-4804Article

Why not breast conservation ?BEAR, H. D.Journal of surgical oncology. 1993, Vol 53, Num 4, pp 211-214, issn 0022-4790Article

Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleensBEAR, H. D.Cancer research (Baltimore). 1986, Vol 46, Num 4, pp 1805-1812, issn 0008-5472Article

Indications for neoadjuvant chemotherapy for breast cancerBEAR, H. D.Seminars in oncology. 1998, Vol 25, Num 2, pp 3-12, issn 0093-7754, SUP3Article

Another view of the tamoxifen trial. CommentaryKAUFMAN, C. S; BEAR, H. D.Journal of surgical oncology. 1999, Vol 72, Num 1, pp 1-8, issn 0022-4790Article

Prognosis of level V malignant melanomaBEAR, H. D; NEIFELD, J. P; KAY, S et al.Cancer. 1985, Vol 55, Num 6, pp 1167-1171, issn 0008-543XConference Paper

Effect of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest, and modulation of drug-induced apoptosis in human myeloid leukemia cellsRAO, A. S; FREEMERMAN, A. J; JARVIS, W. D et al.Leukemia. 1996, Vol 10, Num 7, pp 1150-1158, issn 0887-6924Article

Precursor frequency analysis of bryostatin activated lymphocytesFLEMING, M. D; BARRETT, S. K; BEAR, H. D et al.The Journal of surgical research. 1994, Vol 57, Num 1, pp 74-79, issn 0022-4804Conference Paper

Generation of cytotoxic T lymphocytes from peripheral bloodMCKINNON, J. G; ALSHAD LALANI; SY, L et al.Surgery. 1993, Vol 113, Num 5, pp 536-540, issn 0039-6060Article

Comparative efficacy of Adjuvant chemotherapy in Patients with Dukes' B versus Dukes' C colon cancer : Results from four National Surgical Adjuvant Breast and Bowel project Adjuvant studies (C-01, C-02, C-03, and C-04)MAMOUNAS, E; WIEOND, S; WOLMARK, N et al.Journal of clinical oncology. 1999, Vol 17, Num 5, pp 1349-1355, issn 0732-183XArticle

Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytesRICE, C. D; BALDWIN, N. G; BIRON, R. T et al.Journal of neuro-oncology. 1997, Vol 32, Num 1, pp 29-38, issn 0167-594XArticle

Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breastHILLNER, B. E; DESCH, C. E; CARLSON, R. W et al.Journal of clinical oncology. 1996, Vol 14, Num 1, pp 70-77, issn 0732-183XArticle

γ-interferon plays a key role in T-cell-induced tumor regressionTUTTLE, T. M; MCCRADY, C. W; INGE, T. H et al.Cancer research (Baltimore). 1993, Vol 53, Num 4, pp 833-839, issn 0008-5472Article

Formal hepatic resection of colorectal liver metastases : ploidy and prognosis. DiscussionLIND, D. S; LIND, D. S et al.PARKER, G. A; LIND, D. S; LIND, D. S et al.Annals of surgery. 1992, Vol 215, Num 6, pp 677-684, issn 0003-4932Conference Paper

Activation and in vitro expansion of tumor-reactive T lymphocytes from lymph nodes draining human primary breast cancerHOOVER, S. K; FRANK, J. L; MCCRADY, C et al.Journal of surgical oncology. 1991, Vol 46, Num 2, pp 117-124, issn 0022-4790Article

Phenotypic and functional heterogeneity of thymic and splenic lymphokine activated killer cells relative to ornithine sensitivityPRITI MEHROTRA NEE TANDON; BEAR, H. D; SUSSKIND, B. M et al.Cellular immunology (Print). 1991, Vol 132, Num 2, pp 451-465, issn 0008-8749Article

Phase Ib trial of bryostatin 1 in patients with refractory malignanciesGRANT, S; ROBERTS, J; POPLIN, E et al.Clinical cancer research. 1998, Vol 4, Num 3, pp 611-618, issn 1078-0432Article

Effect of preoperative chemotherapy on the outcome of women with operable breast cancerFISHER, B; BRYANT, J; MARGOLESE, R. G et al.Journal of clinical oncology. 1998, Vol 16, Num 8, pp 2672-2685, issn 0732-183XArticle

Long-term results of breast conservation therapy for breast cancer. DiscussionNEFF, P. T; BEAR, H. D; FOSTER, R. S et al.Annals of surgery. 1996, Vol 223, Num 6, pp 709-717, issn 0003-4932Conference Paper

Different signaling pathways induced by α-CD3 monoclonal antibody versus alloantigen on the basis of differential ornithine sensitivityPRITI MEHROTRA NEE TANDON; LIND, D. S; BEAR, H. D et al.Cellular immunology (Print). 1992, Vol 143, Num 1, pp 41-54, issn 0008-8749Article

Stage III breast cancer : is neoadjuvant chemotherapy always necessary ?FRANK, J. L; MCCLISH, D. K; DAWSON, K. S et al.Journal of surgical oncology. 1992, Vol 49, Num 4, pp 220-225, issn 0022-4790Article

Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor β₁INGE, T. H; HOOVER, S. K; SUSSKIND, B. M et al.Cancer research (Baltimore). 1992, Vol 52, Num 6, pp 1386-1392, issn 0008-5472Article

Bryostatin 1-activated T cells can traffic and mediate tumor regressionTUTTLE, T. M; BETHKE, K. P; INGE, T. H et al.The Journal of surgical research. 1992, Vol 52, Num 6, pp 543-548, issn 0022-4804Conference Paper

Cyclophosphamide and abrogation of tumor-induced suppressor T cell activityHOOVER, S. K; BARRETT, S. K; TURK, T. M. T et al.Cancer immunology and immunotherapy. 1990, Vol 31, Num 2, pp 121-127, issn 0340-7004, 7 p.Article

Evaluation of stereotactic core needle biopsy (SCNB) of the breast at a single institutionLATOSINSKY, S; CORNELL, D; BEAR, H. D et al.Breast cancer research and treatment. 2000, Vol 60, Num 3, pp 277-283, issn 0167-6806Article